Teva Pharmaceutical Industries Ltd. has agreed to pay $1.2 billion in a settlement with the U.S. Federal Trade Commission (FTC), resolving claims that Cephalon Inc. blocked generic drug competition. Teva acquired Cephalon in 2012.
The FTC will hold the settlement money to compensate drug purchasers, including wholesalers, pharmacies and insurers, who overpaid for the sleep-disorder drug Provigil because of Cephalon’s illegal conduct, the commission said.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
In a statement the FTC said: “Today’s landmark settlement is an important step in the FTC’s ongoing effort to protect consumers from anti-competitive pay-for-delay settlements.”
The settlement comes ahead of proceedings that were scheduled to begin Monday in a Philadelphia federal court.
Teva made way for its $40.1 billion takeover of rival drug maker Mylan NV in a deal that would add to a record period of consolidation in the pharmaceutical industry.
READ our report on that matter HERE